| Peptor Ltd. | |||
| Proposed Ticker: | PEPTF | ||
| Exchange: | NASDAQ-National Market | ISRAL | |
| Industry: | Manufacturing (SIC Code 2836) | ||
| Type of Shares: | Ordinary Shares | Filing Date: | 6/20/97 | |
| U.S. Shares Filed: | 2,000,000 | Filing Range: | $14.00 - $16.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 2,000,000 | Expenses: | - | |
| Secondary Shares: | 0 | Shares Out After: | 7,693,190 |
| Manager | Tier | Phone |
| CS First Boston | Lead Manager | (212) 325-2000 |
| Volpe Brown Whelan & Company | Co-manager | (415) 274-4463 |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 3/31/97 | |||||
| Revenue: | $0.00 | Assets: | |||
| Net Income: | -$0.90 | Curr Assets: | |||
| EPS: | -$0.16 | Liabilities: | |||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | Equity: | ||||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is an Israeli drug development company. Peptor's drug technology is still in the development stage and has not yet generated revenue. The company is researching treatments for cancer, rheumatiod arthritis, multiple sclerosis and HIV. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, for the purchase and maintenance of laboratory equipment and facilities, working capital and general corporate purposes, and possible construction of facilities or acquisition of business products. |